Molecular mechanism of epigallocatechin-3-gallate in human esophageal squamous cell carcinoma in vitro and in vivo

Oncology Reports

Volumn 33, Issue 1, 2015, Pages 297-303

  Liu, Lifeng ^a   Hou, Lei ^b   Gu, Shanzhi ^c   Zuo, Xiaoxiao ^a   Meng, Du ^a   Luo, Minna ^a   Zhang, Xiaojin ^a   Huang, Shangke ^a   Zhao, Xinhan ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b SHAANXI PROVINCIAL PEOPLE S HOSPITAL   (China)

^c MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

Author keywords

Apoptosis; Caspase 3; EGCG; ESCC; ROS; VEGF

Indexed keywords

ANNEXIN; CASPASE 3; EPIGALLOCATECHIN GALLATE; PROPIDIUM IODIDE; REACTIVE OXYGEN METABOLITE; VASCULOTROPIN; ANTINEOPLASTIC AGENT; CASP3 PROTEIN, HUMAN; CATECHIN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CELL CYCLE G1 PHASE; CELL VIABILITY; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOLECULAR MECHANICS; NONHUMAN; PROTEIN EXPRESSION; RAT; SQUAMOUS CELL CARCINOMA CELL LINE; TUMOR XENOGRAFT; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANIMAL; BAGG ALBINO MOUSE; CARCINOMA, SQUAMOUS CELL; CELL PROLIFERATION; DRUG EFFECTS; DRUG SCREENING; ESOPHAGEAL NEOPLASMS; G1 PHASE CELL CYCLE CHECKPOINT; METABOLISM; NUDE MOUSE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CASPASE 3; CATECHIN; CELL LINE, TUMOR; CELL PROLIFERATION; ESOPHAGEAL NEOPLASMS; G1 PHASE CELL CYCLE CHECKPOINTS; HUMANS; MALE; MICE, INBRED BALB C; MICE, NUDE; REACTIVE OXYGEN SPECIES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84916227120     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3555     Document Type: Article

References (39)

1. Demeester SR: Epidemiology and biology of esophageal cancer. Gastrointest Cancer Res 3 (Suppl 1): S2-S5, 2009.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
3. Chowdhury FU, Bradley KM and Gleeson FV: The role of 18F-FDG PET/CT in the evaluation of oesophageal carcinoma. Clin Radiol 63: 1297-1309, 2008.
4. Choi J, Kim SG, Kim JS, Jung HC and Song IS: Comparison of endoscopic ultrasonography (EUS), positron emission tomography (PET), and computed tomography (CT) in the preoperative locoregional staging of resectable esophageal cancer. Surg Endosc 24: 1380-1386, 2010.
5. Salahudeen HM, Balan A, Naik K, Mirsadraee S and Scarsbrook AF: Impact of the introduction of integrated PET-CT into the preoperative staging pathway of patients with potentially operable oesophageal carcinoma. Clin Radiol 63: 765-773, 2008.
6. Noble F, Bailey D; SWCIS Upper Gastrointestinal Tumour Panel, Tung K and Byrne JP: Impact of integrated PET/CT in the staging of oesophageal cancer: a UK population-based cohort study. Clin Radiol 64: 699-705, 2009.
7. Abou El Naga RN, Azab SS, El-Demerdash E, Shaarawy S, El-Merzabani M and Ammar el-SM: Sensitization of TRAILinduced apoptosis in human hepatocellular carcinoma HepG2 cells by phytochemicals. Life Sci 92: 555-561, 2013.
8. Farabegoli F, Papi A, Bartolini G, Ostan R and Orlandi M: (-)-Epigallocatechin-3-gallate downregulates Pg-P and BCRP in a tamoxifen resistant MCF-7 cell line. Phytomedicine 17: 356-362, 2010.
9. Lee SH, Nam HJ, Kang HJ, Kwon HW and Lim YC: Epigallocatechin-3-gallate attenuates head and neck cancer stem cell traits through suppression of Notch pathway. Eur J Cancer 49: 3210-3218, 2013.
10. Lecumberri E, Dupertuis YM, Miralbell R and Pichard C: Green tea polyphenol epigallocatechin-3-gallate (EGCG) as adjuvant in cancer therapy. Clin Nutr 32: 894-903, 2013.
11. Qian Y, Guan T, Huang M, et al: Neuroprotection by the soy isoflavone, genistein, via inhibition of mitochondria-dependent apoptosis pathways and reactive oxygen induced-NF-κB activation in a cerebral ischemia mouse model. Neurochem Int 60: 759-767, 2012.
12. Forbes-Hernández TY, Giampieri F, Gasparrini M, Mazzoni L, Quiles JL, Alvarez-Suarez JM and Battino M: The effects of bioactive compounds from plant foods on mitochondrial function: a focus on apoptotic mechanisms. Food Chem Toxicol 68: 154-182, 2014.
13. Kwak TW, Kim do H, Chung CW, Lee HM, Kim CH, Jeong YI and Kang DH: Synergistic anticancer effects of vorinostat and epigallocatechin-3-gallate against HuCC-T1 human cholangiocarcinoma cells. Evid Based Complement Alternat Med 2013: 185158, 2013.
14. Lee JH, Jeong YJ, Lee SW, et al: EGCG induces apoptosis in human laryngeal epidermoid carcinoma Hep2 cells via mitochondria with the release of apoptosis-inducing factor and endonuclease G. Cancer Lett 290: 68-75, 2010.
15. Sakamoto Y, Terashita N, Muraguchi T, Fukusato T and Kubota S: Effects of epigallocatechin-3-gallate (EGCG) on A549 lung cancer tumor growth and angiogenesis. Biosci Biotechnol Biochem 77: 1799-1803, 2013.
16. Spagnuolo P, Rasini E, Luini A, et al: Isoflavone content and estrogenic activity of different batches of red clover (Trifolium pratense L.) extracts: an in vitro study in MCF-7 cells. Fitoterapia 94: 62-69, 2014.
17. Eskandani M, Hamishehkar H and Ezzati Nazhad Dolatabadi J: Cytotoxicity and DNA damage properties of tert-butylhydroquinone (TBHQ) food additive. Food Chem 153: 315-320, 2014.
18. Valenti D, de Bari L, Manente GA, Rossi L, Mutti L, Moro L and Vacca RA: Negative modulation of mitochondrial oxidative phosphorylation by epigallocatechin-3 gallate leads to growth arrest and apoptosis in human malignant pleural mesothelioma cells. Biochim Biophys Acta 1832: 2085-2096, 2013.
19. Tran PL, Kim SA, Choi HS, Yoon JH and Ahn SG: Epigallocatechin-3-gallate suppresses the expression of HSP70 and HSP90 and exhibits anti-tumor activity in vitro and in vivo. BMC Cancer 10: 276, 2010.
20. Hwang YS, Park KK and Chung WY: Epigallocatechin-3 gallate inhibits cancer invasion by repressing functional invadopodia formation in oral squamous cell carcinoma. Eur J Pharmacol 715: 286-295, 2013.
21. Singh M, Singh R, Bhui K, Tyagi S, Mahmood Z and Shukla Y: Tea polyphenols induce apoptosis through mitochondrial pathway and by inhibiting nuclear factor-κB and Akt activation in human cervical cancer cells. Oncol Res 19: 245-257, 2011.
22. Shan X, Li Y, Meng X, Wang P, Jiang P and Feng Q: Curcumin and (-)-epigallocatechin-3-gallate attenuate acrylamide-induced proliferation in HepG2 cells. Food Chem Toxicol 66: 194-202, 2014.
23. Ma J, Shi M, Li G, et al: Regulation of Id1 expression by epigallocatechin-3-gallate and its effect on the proliferation and apoptosis of poorly differentiated AGS gastric cancer cells. Int J Oncol 43: 1052-1058, 2013.
24. Thakur VS, Ruhul Amin AR, Paul RK, et al: p53-Dependent p21-mediated growth arrest pre-empts and protects HCT116 cells from PUMA-mediated apoptosis induced by EGCG. Cancer Lett 296: 225-232, 2010.
25. Tsai CF, Hsu YW, Ting HC, Huang CF and Yen CC: The in vivo antioxidant and antifibrotic properties of green tea (Camellia sinensis, Theaceae). Food Chem 136: 1337-1344, 2013.
26. Kim HS, Quon MJ and Kim JA: New insights into the mechanisms of polyphenols beyond antioxidant properties; lessons from the green tea polyphenol, epigallocatechin 3-gallate. Redox Biol 2: 187-195, 2014.
27. Satoh M, Takemura Y, Hamada H, Sekido Y and Kubota S: EGCG induces human mesothelioma cell death by inducing reactive oxygen species and autophagy. Cancer Cell Int 13: 19, 2013.
28. Manohar M, Fatima I, Saxena R, Chandra V, Sankhwar PL and Dwivedi A: (-)-Epigallocatechin-3-gallate induces apoptosis in human endometrial adenocarcinoma cells via ROS generation and p38 MAP kinase activation. J Nutr Biochem 24: 940-947, 2013.
29. Kalaiselvi P, Rajashree K, Bharathi Priya L and Padma VV: Cytoprotective effect of epigallocatechin-3-gallate against deoxynivalenol-induced toxicity through anti-oxidative and antiinflammatory mechanisms in HT-29 cells. Food Chem Toxicol 56: 110-118, 2013.
30. Susin SA, Lorenzo HK, Zamzami N, et al: Molecular characterization of mitochondrial apoptosis-inducing factor. Nature 397: 441-446, 1999.
31. Gao Y, Li W, Jia L, Li B, Chen YC and Tu Y: Enhancement of (-)-epigallocatechin-3-gallate and theaflavin-3-3′-digallate induced apoptosis by ascorbic acid in human lung adenocarcinoma SPC-A-1 cells and esophageal carcinoma Eca-109 cells via MAPK pathways. Biochem Biophys Res Commun 438: 370-374, 2013.
32. Deindl E: Mechanistic insights into the functional role of vascular endothelial growth factor and its signalling partner brain-derived neurotrophic factor in angiogenic tube formation. Acta Physiol 211: 268-270, 2014.
33. Gorman JL, Liu ST, Slopack D, et al: Angiotensin II evokes angiogenic signals within skeletal muscle through co-ordinated effects on skeletal myocytes and endothelial cells. PLoS One 9: e85537, 2014.
34. Takala H, Saarnio J, Wiik H, Ohtonen P and Soini Y: HIF-1α and VEGF are associated with disease progression in esophageal carcinoma. J Surg Res 167: 41-48, 2011.
35. Hsieh DS, Wang H, Tan SW, Huang YH, Tsai CY, Yeh MK and Wu CJ: The treatment of bladder cancer in a mouse model by epigallocatechin-3-gallate-gold nanoparticles. Biomaterials 32: 7633-7640, 2011.
36. Shimizu M, Shirakami Y, Sakai H, et al: (-)-Epigallocatechin gallate inhibits growth and activation of the VEGF/VEGFR axis in human colorectal cancer cells. Chem Biol Interact 185: 247-252, 2010.
37. Valenti D, De Rasmo D, Signorile A, et al: Epigallocatechin-3-gallate prevents oxidative phosphorylation deficit and promotes mitochondrial biogenesis in human cells from subject with Down's syndrome. Biochim Biophys Acta 1832: 542-552, 2013.
38. Galati G, Lin A, Sultan AM and O'Brien PJ: Cellular and in vivo hepatotoxicity caused by green tea phenolic acids and catechins. Free Radic Biol Med 40: 570-580, 2006.
39. Min NY, Kim JH, Choi JH, et al: Selective death of cancer cells by preferential induction of reactive oxygen species in response to (-)-epigallocatechin-3-gallate. Biochem Biophys Res Commun 421: 91-97, 2012.